CNS Pharmaceuticals (CNSP) Other financing activities (2020 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Other financing activities came in at $844.0 in Q3 2025, down 69.67% on a QoQ basis from $2783.0 in Q2 2025.
CNS Pharmaceuticals (CNSP) Other financing activities (2020 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 6 years of Other financing activities data on file, last reported at $844.0 in Q3 2025.
- Quarterly Other financing activities changed N/A year-over-year to $844.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $3627.0 (down 82.99% YoY) and the FY2025 annual result came in at $3627.0, down 82.99% from the prior year.
- Other financing activities retreated to $844.0 in Q3 2025, from $2783.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $2.2 million in Q4 2023 to a low of -$1.0 in Q4 2024.
- A 5-year average of $301970.5 and a median of $2783.0 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities soared 1894451.69% — and 2024, when it sank 100.0%.
- Tracing CNSP's Other financing activities over 5 years: stood at $332750.0 in 2021, then plunged by 99.96% to $118.0 in 2022, then soared by 1894451.69% to $2.2 million in 2023, then sank by 100.0% to -$1.0 in 2024, then jumped by 84500.0% to $844.0 in 2025.
- The last three Other financing activities figures came in at $844.0 (Q3 2025), $2783.0 (Q2 2025), and -$1.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 844.00 |
| Sep 30, 2025 | 844.00 |
| Jun 30, 2025 | 2,783.00 |
| Jun 30, 2025 | 2,783.00 |
| Dec 31, 2024 | -1.00 |
| Dec 31, 2024 | -1.00 |
| Jun 30, 2024 | 8,921.00 |
| Jun 30, 2024 | 8,921.00 |
| Mar 31, 2024 | 12,405.00 |
| Mar 31, 2024 | 12,405.00 |
| Dec 31, 2023 | 2.24 Mn |
| Dec 31, 2023 | 2.24 Mn |
| Jun 30, 2023 | 725,059.00 |
| Jun 30, 2023 | 725,059.00 |
| Mar 31, 2023 | 609.00 |
| Mar 31, 2023 | 609.00 |
| Dec 31, 2022 | 118.00 |
| Dec 31, 2022 | 118.00 |
| Mar 31, 2022 | 2,616.00 |
| Mar 31, 2022 | 2,616.00 |